eng Science and Education Publishing International Journal of Hematological Disorders 2014-12-09 1 1A 7 12 10.12691/ijhd-1-1A-2 IJHD201411A2 article Is There Still a Role for High-Dose Melphalan and Stem Cell Transplantation in the Treatment of Multiple Myeloma? Morie A. Gertz gertz.morie@mayo.edu 1 Francis K. Buadi 1 Martha Q. Lacy 1 Department of Medicine, College of Medicine, Mayo Distinguished Clinician, Rochester Stem cell transplantation was demonstrated to have a survival value in the era prior to the introduction of novel agents for the treatment of multiple myeloma. It has become reasonable to begin to question the value of stem cell transplantation. In this review, we analyzed available data and ongoing trials to determine whether or not the evidence is sufficient to continue using stem cell transplantation as a primary modality for the treatment of the eligible patient with multiple myeloma. http://pubs.sciepub.com/ijhd/1/1A/2/ijhd-1-1A-2.pdf high-dose melphalan stem cell transplantation multiple myeloma bortezomib lenalidomide; thalidomide